SavedAdd your journal

Journals / Annals of Medical Research / 2018 / Cilt: 25 - Sayı: 2

Protective effects of puerarin on the periodontium in an experimental rat model of periodontitis with and without diabetes mellitus: A stereological and immunohistochemical study

Gamze ALTUN
Akif TURER
Çiğdem COŞKUN TÜRER
Pages
169–175
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

MMP-9, TIMP-1 levels and RANKL/OPG ratio were evaluated immunohistochemically.Results: Significantreduced alveolar bone and attachment losses were found in puerarin-treated groups comparing to in salineadministered groups (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Periodontitis is a chronic inflammatory disease characterized by tissue destruction.
📊
Key Findings & Data:Diabetes was induced by injection of streptozocin (200 mg/kg).
💡
Conclusion & Impact:MMP-9, TIMP-1 levels and RANKL/OPG ratio were evaluated immunohistochemically.Results: Significantreduced alveolar bone and attachment losses were found in puerarin-treated groups comparing to in salineadministered groups (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Periodontitis is a chronic inflammatory disease characterized by tissue destruction. Patients with diabetes mellitus are moresusceptible to severe tissue destruction. Puerarin, a biological component derived from Pueraria lobate, has anti-inflammatory and anti-diabetic effects. The purpose of the study is to evaluate the protective role of puerarin on alveolar bone loss and connective tissue destruction in ligature induced diabetic and non-diabetic rats.Material and methods: Sixty rats were divided as non-diabetic control, non-diabetic-experimental periodontitis (EP)-systemic saline, non-diabetic-EP-systemic puerarin, diabetic control, diabetic-EP-systemic saline and diabetic-EP-systemic puerarin. Diabetes was induced by injection of streptozocin (200 mg/kg). EP was achieved by placing a sterile silk suture around the first molars into the gingival sulcus for 15 days. In puerarin treated groups, 200 mg/kg puerarin was applied daily for 15 days beginning one-day prior the placement of the ligature. The alveolar bone level of the first molar tooth, alveolar bone ratio in the furcation area and the attachment level were evaluated histologically. MMP-9, TIMP-1 levels and RANKL/OPG ratio were evaluated immunohistochemically.Results: Significantreduced alveolar bone and attachment losses were found in puerarin-treated groups comparing to in salineadministered groups (p

🔖

Cite This Article

ALTUN, G., TURER, A., TÜRER, Ç. C. (2022). Protective effects of puerarin on the periodontium in an experimental rat model of periodontitis with and without diabetes mellitus: A stereological and immunohistochemical study. Annals of Medical Research, Cilt: 25 - Sayı: 2, 169–175. https://ajindex.com/articles/447220

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Zhang Y, Yan M, Yu QF, Yang PF, Zhang HD, Sun YH, et al. Puerarin Prevents LPS-Induced Osteoclast Formation and Bone Loss via Inhibition of Akt Activation. Bio Pharm Bull 2016;39(12):2028-35. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984;134(Pt 2):127-36.
  2. Yuan SY, Sheng T, Liu LQ, Zhang YL, Liu XM, Ma T, et al. Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro. Chin J Nat Med 2016;14(4):265-9.
  3. Yang X, Zhang H, Wang J, Zhang Z, Li C. Puerarin decreases bone loss and collagen destruction in rats with ligatureinduced periodontitis. J Periodontal Res 2015;50(6):748-57.
  4. Wang Y, Yang C, Xie WL, Zhao YW, Li ZM, Sun WJ, et al. Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-kappaB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells. Phytomedicine 2014;21(8-9):1032-6.
  5. Turer CC, Turer A, Durmuslar MC, Onger ME. The local effect of puerarin on critical-sized calvarial defects. J Craniofac Surg 2017;28(1):143-6.
  6. Kuhr A, Popa-Wagner A, Schmoll H, Schwahn C, Kocher T. Observations on experimental marginal periodontitis in rats. J Periodontal Res 2004;39(2):101-6.
  7. Rovin S, Costich ER, Gordon HA. The influence of bacteria and irritation in the initiation of periodontal disease in germfree and conventional rats. J Periodontal Res 1966;183):193-204.
  8. Graves DT, Fine D, Teng YT, Van Dyke TE, Hajishengallis G. The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J Clin Periodontol 2008;35(2):89-105.
  9. Xu L, Zheng N, He Q, Li R, Zhang K, Liang T. Puerarin, isolated from Pueraria lobata (Willd.), protects against hepatotoxicity via specific inhibition of the TGF-β1/Smad signaling pathway, thereby leading to anti-fibrotic effect. Phytomedicine 2013;20(13):1172-9.
  10. Zhang W, Liu CQ, Wang PW, Sun SY, Su WJ, Zhang HJ, et al. Puerarin improves insulin resistance and modulates adipokine expression in rats fed a high-fat diet. Eur J Pharmacol 2010;649:398-402.
  11. Pan X, Wang J, Pu Y, Yao J, Wang H. Effect of puerarin on expression of ICAM-1 and TNF-alpha in kidneys of diabetic rats. Med Sci Monit 2015;21:2134-40.
  12. Kato E, Kawabata J. Glucose uptake enhancing activity of puerarin and the role of C-glucoside suggested from activity of related compounds. Bioorg Med Chem Lett 2010;20(15):4333-6.
  13. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resista